Reducing allergenicity by altering allergen fold: A mosaic protein of Phl p 1 for allergy vaccination

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 64, Issue 4, 2009, Pages 569-580

  Ball, T ^a   Linhart, B ^a   Sonneck, K ^a   Blatt, K ^a   Herrmann, H ^a   Valent, P ^a   Stoecklinger, A ^b   Lupinek, C ^a   Thalhamer, J ^b   Fedorov, A A ^c   Almo, S C ^c   Valenta, R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Allergens; Immunotherapy; Pollens

Indexed keywords

ALU GEL S; ALUMINUM HYDROXIDE; COMPLEMENTARY DNA; GRASS POLLEN VACCINE; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; POLLEN ANTIGEN; RECOMBINANT PHLEUM PRATENSE 1 ANTIGEN; RECOMBINANT PHLEUM PRATENSE 1 MOSAIC PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALLERGENICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; BAGG ALBINO MOUSE; BASOPHIL DEGRANULATION; CELL ACTIVATION; CIRCULAR DICHROISM; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MODIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOREACTIVITY; MALE; MOSAICISM; NONHUMAN; NUCLEOTIDE SEQUENCE; PHLEUM PRATENSE; POLLEN ALLERGY; PRIORITY JOURNAL; PROTEIN FOLDING; RABBIT;

ADULT; AGED; ALLERGENS; AMINO ACID SEQUENCE; ANIMALS; BASOPHILS; DESENSITIZATION, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FEMALE; HISTAMINE; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PLANT PROTEINS; POLYMERASE CHAIN REACTION; PROTEIN STRUCTURE, QUATERNARY; RABBITS; RATS; RECOMBINANT PROTEINS; RHINITIS, ALLERGIC, SEASONAL; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; T-LYMPHOCYTES;

EID: 62449174319     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2008.01910.x     Document Type: Article

References (50)

1. Wüthrich B, Schindler C, Leuenberger P, Ackermann-Liebrich U. Prevalence of atopy and pollinosis in the adult population of Switzerland (SAPALDIA study). Swiss Study on Air Pollution and Lung Diseases in Adults. Int Arch Allergy Immunol 1995 106 : 149 156.
2. Floistrup H, Swartz J, Bergstrom A, Alm JS, Scheynius A, van Hage M et al. The Parsifal Study. Allergic disease and sensitization in Steiner school children. J Allergy Clin Immunol 2006 117 : 59 66.
3. Bischoff SC. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol 2007 7 : 93 104.
4. Valenta R, Ball T, Focke M, Linhart B, Mothes N, Niederberger V et al. Immunotherapy of allergic disease. Adv Immunol 2004 82 : 105 153.
5. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006 6 : 761 771.
6. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998 102 : 558 562.
7. Esch RE. Evaluation of allergen vaccine potency. Curr Allergy Asthma Rep 2006 6 : 402 406.
8. Valerio CR, Murray P, Arlian LG, Slater JE. Bacterial 16S ribosomal DNA in house dust mite cultures. J Allergy Clin Immunol 2005 116 : 1296 1300.
9. Trivedi B, Valerio C, Slater JE. Endotoxin content of standardized allergen vaccines. J Allergy Clin Immunol 2003 111 : 777 783.
10. Focke M, Marth K, Flicker S, Valenta R. Heterogeneity of commercial timothy grass pollen extracts. Clin Exp Allergy 2008 38 : 1400 1408.
11. Winther L, Arnved J, Malling HJ, Nolte H, Mosbech H. Side-effects of allergen-specific immunotherapy: a prospective multi-centre study. Clin Exp Allergy 2006 36 : 254 260.
12. Valenta R, Kraft D. From allergen structure to new forms of allergen-specific immunotherapy. Curr Opin Immunol 2002 14 : 718 727.
13. Linhart B, Valenta R. Molecular design of allergy vaccines. Curr Opin Immunol 2005 17 : 646 655.
14. Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 2004 113 : 1144 1151.
15. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006 355 : 1445 1455.
16. Singh MB, de Weerd N, Bhalla PL. Genetically engineered plant allergens with reduced anaphylactic activity. Int Arch Allergy Immunol 1999 119 : 75 85.
17. Johnson P, Marsh DG. 'Isoallergens' from rye grass pollen. Nature 1965 206 : 935 937.
18. Freidhoff LR, Ehrlich-Kautzky E, Grant JH, Meyers DA, Marsh DG. A study of the human immune response to Lolium perenne (rye) pollen and its components, Lol p I and Lol p II (rye I and rye II). I. Prevalence of reactivity to the allergens and correlations among skin test, IgE antibody, and IgG antibody data. J Allergy Clin Immunol 1986 78 : 1190 1201.
19. Laffer S, Duchene M, Reimitzer I, Susani M, Mannhalter C, Kraft D et al. Common IgE-epitopes of recombinant Phl p I, the major timothy grass pollen allergen and natural group I grass pollen isoallergens. Mol Immunol 1996 33 : 417 426.
20. Niederberger V, Laffer S, Froschl R, Kraft D, Rumpold H, Kapiotis S et al. IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE. J Allergy Clin Immunol 1998 101 : 258 264.
21. Schenk S, Breiteneder H, Susani M, Najafian N, Laffer S, Duchene M et al. T-cell epitopes of Phl p 1, major pollen allergen of timothy grass (Phleum pratense): evidence for crossreacting and non-crossreacting T-cell epitopes within grass group I allergens. J Allergy Clin Immunol 1995 96 : 986 996.
22. Ball T, Vrtala S, Sperr WR, Valent P, Susani M, Kraft D et al. Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction. J Biol Chem 1994 269 : 28323 28328.
23. Ball T, Fuchs T, Sperr WR, Valent P, Vangelista L, Kraft D et al. B cell epitopes of the major timothy grass pollen allergen, phl p 1, revealed by gene fragmentation as candidates for immunotherapy. The FASEB J 1999 13 : 1277 1290.
24. Vrtala S, Susani M, Sperr WR, Valent P, Laffer S, Dolecek C et al. Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p 2, Phl p 5). J Allergy Clin Immunol 1996 97 : 781 787.
25. Valenta R, Duchene M, Pettenburger K, Sillaber C, Valent P, Bettelheim P et al. Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals. Science 1991 253 : 557 560.
26. Gill SC, von Hippel PH. Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem 1989 82 : 319 326.
27. Lobley A, Whitmore L, Wallace BA. DICHROWEB: an interactive website for the analysis of protein secondary structure from circular dichroism spectra. Bioinformatics 2002 18 : 211 212.
28. Whitmore L, Wallace BA. DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. Nucleic Acids Res 2004 32 : W668 W673.
29. Hauswirth AW, Natter S, Ghannadan M, Majlesi Y, Schernthaner GH, Sperr WR et al. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol 2002 110 : 102 109.
30. Valent P, Besemer S, Muhm M, Majdic O, Lechner K, Bettelheim P. Interleukin 3 activates human blood basophils via high-affinity binding sites. Proc Natl Acad Sci USA 1989 86 : 5542 5546.
31. Ebner C, Szepfalusi S, Ferreira F, Jilek A, Valenta R, Parronchi P et al. Identification of multiple T cell epitopes on Bet v I, the major birch pollen allergen, using specific T cell clones and overlapping peptides. J Immunol 1993 150 : 1047 1054.
32. Vrtala S, Ball T, Spitzauer S, Pandjaitan P, Suphioglu C, Knox B et al. Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. J Immunol 1998 160 : 6137 6144.
33. Kaul S, Luttkopf D, Kastner B, Vogel L, Holtz G, Vieths S et al. Mediator release assays based on human or murine immunoglobulin E in allergen standardization. Clin Exp Allergy 2007 37 : 141 150.
34. Westritschnig K, Focke M, Verdino P, Goessler W, Keller W, Twardosz A et al. Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7. J Immunol 2004 172 : 5684 5692.
35. Ball T, Edstrom W, Mauch L, Schmitt J, Leistler B, Fiebig H et al. Gain of structure and IgE epitopes by eukaryotic expression of the major Timothy grass pollen allergen, Phl p 1. FEBS J 2005 272 : 217 227.
36. Suck R, Kamionka T, Schaffer B, Wahl R, Nandy A, Weber B et al. Bacterially expressed and optimized recombinant Phl p 1 is immunobiochemically equivalent to natural Phl p 1. Biochim Biophys Acta 2006 1764 : 1701 1709.
37. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004 101 : 14677 14682.
38. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005 116 : 608 613.
39. Reisinger J, Horak F, Pauli G, van Hage M, Cromwell O, Konig F et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol 2005 116 : 347 354.
40. Gafvelin G, Thunberg S, Kronqvist M, Gronlund H, Gronneberg R, Troye-Blomberg M et al. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol 2005 138 : 59 66.
41. Niederberger V, Reisinger J, Valent P, Krauth MT, Pauli G, van Hage M et al. Vaccination with genetically modified birch pollen allergens: immune and clinical effects on oral allergy syndrome. J Allergy Clin Immunol 2007 119 : 1013 1016.
42. Valenta R, Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007 119 : 826 830.
43. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002 2 : 446 453.
44. van Neerven RJ, Knol EF, Ejrnaes A, Würtzen PA. IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy. Int Arch Allergy Immunol 2006 141 : 119 129.
45. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003 112 : 915 922.
46. Moverare R, Elfman L, Vesterinen E, Metso T, Haahtela T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 2002 57 : 423 430.
47. Andersson K, Lidholm J. Characteristics and immunobiology of grass pollen allergens. Int Arch Allergy Immunol 2003 130 : 87 107.
48. Schramm G, Kahlert H, Suck R, Weber B, Stuwe HT, Muller WD et al. "Allergen engineering": variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. J Immunol 1999 162 : 2406 2414.
49. Vrtala S, Focke M, Kopec J, Verdino P, Hartl A, Sperr WR et al. Genetic engineering of the major timothy grass pollen allergen, Phl p 6, to reduce allergenic activity and preserve immunogenicity. J Immunol 2007 179 : 1730 1739.
50. Mothes-Luksch N, Stumvoll S, Linhart B, Focke M, Krauth MT, Hauswirth A et al. Disruption of allergenic activity of the major grass pollen allergen Ph1 p 2 by reassembly as a mosaic protein. J Immunol 2008 181 : 4864 4873.